Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-24.0,  Virus Disease DNA Virus Infections Hepadnaviridae Infections A group (A1-A2)Subjects born to a mother positive for both HBsAg and hepatitis B e antigen. • Healthy male and female full-term (37-42 weeks gestation) neonates (birth to 1 day of age) • Subjects with a 5-minute Apgar score ≥ 7. • Subjects with temperature <37.1°C on axillary setting • Subjects with a birth weight ≥ 2.5 kg. • Normal neonatal jaundice Written informed consent obtained from the parent(s) of the subject Subjects who the investigator believes that their parent(s) can and will comply with the requirements of the protocol. 2. B group(B1-B2) Subjects born to a mother positive for HBsAg, but negative for the hepatitis B e antigen. • Healthy male and female full-term (37-42 weeks gestation) neonates (birth to 1 day of age) • Subjects with a 5-minute Apgar score ≥ 7. • Subjects with temperature <37.1°C on axillary setting • Subjects with a birth weight ≥2.5 kg. • Normal neonatal jaundice. • Written informed consent obtained from the parent(s) of the subject. • Subjects who the investigator believes that their parent(s) can and will comply with the requirements of the protocol 3. C group（C1-C3）Subjects born to a mother negative for HBsAg, hepatitis Be Antigen, antibody to hepatitis B core antigen, antibody to hepatitis B e-antigen Healthy male and female full-term (37-42 weeks gestation) neonates (birth to 1 day of age) Subjects with a 5-minute Apgar score ≥ 7 Subjects with temperature <37.1°C on axillary setting Subjects with a birth weight ≥ 2.5 kg Normal neonatal jaundice Written informed consent obtained from the parent(s) of the subject Subjects who the investigator believes that their parent(s) can and will comply with the requirements of the protocol  A group (A1-A2) Subjects born to a mother positive for both HBsAg and e Antigen for the first shot • Subjects born to a mother positive for antibody to HBsAg. • Family history of seizures or progressive neurological disease. • Family history of congenital or hereditary immunodeficiency. • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. • Subjects born to a mother had administrated of immunoglobulins and/or any blood products during the pregnancy. • Use of any investigational or non-registered product other than the study vaccines since birth, or planned use during the study period. • Born to a mother known or suspected to be positive for HIV Family history of congenital or hereditary immunodeficiency Children in care Neonatal jaundice requiring systemic treatment Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period Major congenital defects or serious chronic illness, including perinatal brain damage Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives for the second and third shots Dysgenopathy